Braxia Scientific (XCNQ:BRAX) Momentum Rank : 0 (As of Jun. 25, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific Momentum Rank?

Braxia Scientific has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Braxia Scientific Momentum Rank Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Braxia Scientific (XCNQ:BRAX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

BRAXF:USA 4960:Germany

Address

700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6

Website

https://www.braxiascientific.com

Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines